Selected Publications

Russell K, Rupp RE, Morales-Ramirez JO, Diaz-Perez C, Andrews AP, Lee AW, Finn TS, Cox KS, Russell AF, Schaller MM, Martin JC, Hyatt DM, Gozlan-Kelner S, Bili A, Coller BG. : A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults Human Vaccines and Immunotherapeutics Feb 2022 Notes: https://doi.org/10.1080/21645515.2022.2046960.

Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P, Dagan R, Richmond P, Wilck M, Vallejos W, Nunn C, McFetridge R, Tamms G, Fu R, Lupinacci R, Musey L, Bickham K: A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine 2022 Notes: Accepted for publication 2022.

Aletaha D, Bingham CO, Karpouzas GA, Takeuchi T, Thorne C, Bili A, Agarwal P, Hsu B,Rao R, Brown K, Tanaka Y : Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE) RMD Open 2021 7: e001465, 2020 Notes: doi:10.1136/rmdopen-2020-001465.

Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y. Toward : Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. Arthritis Rheumatol 71(12): 1976-1984, Dec 2019 Notes: doi: 10.1002/art.41043.

Sharma T, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A.: Hydroxychloroquine use is Associated with Decreased Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc. 5(1): e002867, Jan 2016 Notes: doi: 10.1161/JAHA.115.002867.

Schroeder LL, Tang X, Wasko MC, Bili A.: Glucocorticoid use is associated with increased HDL in rheumatoid arthritis patients. Rheumatol Int. 35(6): 1059-67, Jun 2015.

Bili A, Tang X, Pranesh S, Bozaite R, Morris S, Antohe J, Kirchner HL. Wasko MC.: TNF-α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66(3): 355-63, Mar 2014 Notes: Oral Presentation

Cote J, Harrington TH, Meadows A, Lin F, Bili A: Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors. The Rheumatologist Nov 2013 Notes: https://www.the-rheumatologist.org/article/fellows-forum-case-report-new-sarcoidosis-cases-in-patients-treated-with-tumor-necrosis-factoralpha-inhibitors/

Cote J, Bili A: Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease. ISRN Rheumatology 2013(589807), 2013 Notes: http://dx.doi.org/10.1155/2013/589807.

Bili A, Morris SJ, Sartorius JA, Kirchner HL, Antohe JA, Dancea S, Wasko MCM: TNF-α inhibitor use is not associated with lipid changes in patients with rheumatoid arthritis. J Rheumatol 39(5): 946-948, 2012.